

1st

Well Aging Society Summit Asia-Japan

Date/Time : 9th October, 2018, 14:00-16:00

Venue : Nihonbashi, Japan (Nihonbashi Life Science Hub)

Purpose :

- (1) Introducing the summary of Ito Review 2.0:Biomedical Edition.
- (2) Presenting the current status of emerging markets for biotech and the desirable direction to support them.
- (3) Discussing what types of IPO or M&A are important for biotech to develop medicines .

【Program】

| | | | | | | | | | | | | | | | | | | | | | | | | | |
|---|--|-----------------------------|----------|-----------------|----------------------------|---------------------------------------|-----------------|-------|-----------------------|--------------|-------------------|------------------|------------|---|--------------------------|---------------|-----------------------------|--------------------------|----------------|--------------------------------|--------------------|--------------|-----------------------------|----------------|-------------------|
| 14:00 – 14:20 | The Background and Key Points of “Ito Review 2.0: Biomedical Edition” Mr. Masahiro Uemura Director, Bio-Industry Division Ministry of Economy, Trade and Industry(METI) | | | | | | | | | | | | | | | | | | | | | | | | |
| 14:20 – 14:35 | The transition of financing environment for biotech in Japan Mr. Yasuyuki Konuma Executive Managing Director(Listings), Tokyo Stock Exchange,Inc.(TSE) | | | | | | | | | | | | | | | | | | | | | | | | |
| 14:35 – 14:50 | Fund Raising Environment for Biotech – Asia, the Advancing Market Mr. Michael Chan Senior Vice President, Hong Kong Exchanges and Clearing (HKEX) | | | | | | | | | | | | | | | | | | | | | | | | |
| 14:50 – 14:55 | Questions and Answers | | | | | | | | | | | | | | | | | | | | | | | | |
| 15:00 – 16:00 | The desirable growth strategy both for biotech and for investors to develop medicines. (Panel Discussion) ※Coordinator : Mr. Keita Maeda (Deputy Director, METI Bio-Industry Division) | | | | | | | | | | | | | | | | | | | | | | | | |
| | <table border="0"> <tbody> <tr> <td>●METI Bio-Industry Division</td> <td>Director</td> <td>Masahiro Uemura</td> </tr> <tr> <td>●Tokyo Stock Exchange,Inc.</td> <td>Executive Managing Director(Listings)</td> <td>Yasuhiro Konuma</td> </tr> <tr> <td>●HKEX</td> <td>Senior Vice President</td> <td>Michael Chan</td> </tr> <tr> <td>●REMIGES Ventures</td> <td>Managing Partner</td> <td>Taro Inaba</td> </tr> <tr> <td>●Shin Nippon Biomedical Laboratories, LTD</td> <td>Executive Vice President</td> <td>Ken Takanashi</td> </tr> <tr> <td>●FAST TRACK INITIATIVE,INC.</td> <td>COO and Managing Partner</td> <td>Tomohiro Anzai</td> </tr> <tr> <td>●UBS Securities Japan Co., Ltd</td> <td>Executive Director</td> <td>Atsushi Seki</td> </tr> <tr> <td>●Mizuho Securities Co., Ltd</td> <td>Senior Analyst</td> <td>Hironoshin Nomura</td> </tr> </tbody> </table> | ●METI Bio-Industry Division | Director | Masahiro Uemura | ●Tokyo Stock Exchange,Inc. | Executive Managing Director(Listings) | Yasuhiro Konuma | ●HKEX | Senior Vice President | Michael Chan | ●REMIGES Ventures | Managing Partner | Taro Inaba | ●Shin Nippon Biomedical Laboratories, LTD | Executive Vice President | Ken Takanashi | ●FAST TRACK INITIATIVE,INC. | COO and Managing Partner | Tomohiro Anzai | ●UBS Securities Japan Co., Ltd | Executive Director | Atsushi Seki | ●Mizuho Securities Co., Ltd | Senior Analyst | Hironoshin Nomura |
| ●METI Bio-Industry Division | Director | Masahiro Uemura | | | | | | | | | | | | | | | | | | | | | | | |
| ●Tokyo Stock Exchange,Inc. | Executive Managing Director(Listings) | Yasuhiro Konuma | | | | | | | | | | | | | | | | | | | | | | | |
| ●HKEX | Senior Vice President | Michael Chan | | | | | | | | | | | | | | | | | | | | | | | |
| ●REMIGES Ventures | Managing Partner | Taro Inaba | | | | | | | | | | | | | | | | | | | | | | | |
| ●Shin Nippon Biomedical Laboratories, LTD | Executive Vice President | Ken Takanashi | | | | | | | | | | | | | | | | | | | | | | | |
| ●FAST TRACK INITIATIVE,INC. | COO and Managing Partner | Tomohiro Anzai | | | | | | | | | | | | | | | | | | | | | | | |
| ●UBS Securities Japan Co., Ltd | Executive Director | Atsushi Seki | | | | | | | | | | | | | | | | | | | | | | | |
| ●Mizuho Securities Co., Ltd | Senior Analyst | Hironoshin Nomura | | | | | | | | | | | | | | | | | | | | | | | |